Immune Repertoire Sequencing Market - Global Forecast to 2030
商品番号 : SMB-77022
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年4月 |
| ページ数 | 371 |
| 図表数 | 589 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period.
世界の免疫レパートリーシークエンシング（IRS）市場は、予測期間中に 9.6% の CAGR で成長し、2025 年の 3 億 3,400 万米ドルから 2030 年には 5 億 6,500 万米ドルに達すると予測されています。
This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.
この市場は、技術の進歩により免疫測定に基づく研究ソリューションの効率、感度、拡張性が向上し続ける中で成長しています。NGS統合、自動液体処理システム、ハイスループットスクリーニングプラットフォームなどの革新により、より迅速かつ正確なアッセイ結果が可能になります。これらの進歩によりワークフローが合理化され、手作業によるエラーが削減され、スループットが向上するため、IRSテクノロジーは研究および臨床アプリケーションにおいてよりアクセスしやすく、信頼性の高いものとなっています。さらに、個別化医療および精密医療への注目が高まる中で、医療提供者や研究者は特定のバイオマーカーを検出し、個々の患者に合わせた治療を行うツールをますます必要としており、IRSソリューションの需要が高まっています。標的療法への移行は、コンパニオン診断、治療モニタリング、個別化治療戦略をサポートするように設計された特定のアッセイキットおよび試薬の開発を促進します。その結果、臨床的意思決定を導き、治療結果を向上させるために、正確で患者中心のデータを提供できる免疫測定テクノロジーのニーズが高まっています。
The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.
In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time—making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.
Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.
Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.
The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.
The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region’s fastest growth during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1—44%, Tier 2—32%, and Tier 3—24%
- By Designation: (Managers)—45%, (CXOs, Directors)—30%, and (Executives)—25%
- By Region: North America—40%, Europe—25%, Asia-Pacific—20%, Rest of the World—15%
List of Companies Profiled in the Report:
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- PacBio (US)
- Oxford Nanopore Technologies PLC (UK)
- 10X Genomics (US)
- QIAGEN (Netherlands)
- Agilent Technologies (US)
- Danaher Corporation (US)
- Takara Bio Inc. (Japan)
- Adaptive Biotechnologies (US)
- BGI Group (China)
- Tecan Trading AG (Switzerland)
- Azenta US Inc. (US)
- Personalis, Inc. (US)
- Creative Biolabs (US)
- Celemics, Inc. (South Korea)
- CellCarta (Canada)
- iRepertoire, Inc. (US)
- New England Biolabs (US)
- Cerba Research (Belgium)
- CeGat GmbH (Germany)
- Element Biosciences (US)
- Seqalis (Belgium)
- Synbio Technologies (China)
- MedGenome (US)
- Enpicom (Netherlands)
Research Coverage:
This report provides a detailed picture of the global IRS market. It aims to estimate the market’s size and future growth potential across different segments such as the product, service, application product-technology, product–end user, service–end user, and region. The report’s scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.
Reasons to Buy this Report :
The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.
- Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market
- Market Development: Comprehensive information about lucrative markets – the report analyses the immune repertoire sequencing market across varied regions.
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key objectives of secondary research 43
2.1.2 PRIMARY DATA 43
2.1.2.1 Breakdown of primaries 44
2.1.2.2 Key objectives of primary research 44
2.2 MARKET ESTIMATION METHODOLOGY 45
2.2.1 GLOBAL MARKET ESTIMATION 45
2.2.1.1 Bottom-up approach 45
2.2.1.2 Insights from primary experts 48
2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 48
2.3 MARKET GROWTH RATE PROJECTION 49
2.4 DATA TRIANGULATION 51
2.5 STUDY ASSUMPTIONS 52
2.6 RESEARCH LIMITATIONS 53
2.7 RISK ANALYSIS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 59
4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW 59
4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY PRODUCT AND COUNTRY 60
4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030 60
4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025 61
4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Increasing technological advancements 63
5.2.1.2 Growing focus on personalized/precision medicines 64
5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring 64
5.2.1.4 Increasing applications in autoimmune disease research 65
5.2.1.5 Rising focus on cancer immunotherapy research 65
5.2.2 RESTRAINTS 66
5.2.2.1 Need for high capital investments 66
5.2.2.2 Limited clinical adoption and validation 66
5.2.3 OPPORTUNITIES 66
5.2.3.1 Integration of AI and ML into immune repertoire sequencing 66
5.2.3.2 Increasing applications in vaccine development 67
5.2.4 CHALLENGES 67
5.2.4.1 Variations in regulatory frameworks and international trade dynamics 67
5.2.4.2 Lack of workflow and data standardization 68
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
5.4 PRICING ANALYSIS 69
5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 69
5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 71
5.5 SUPPLY CHAIN ANALYSIS 72
5.6 VALUE CHAIN ANALYSIS 73
5.7 ECOSYSTEM ANALYSIS 75
5.7.1 ROLE IN ECOSYSTEM 76
5.7.1.1 Product providers 76
5.7.1.2 Service providers 76
5.7.1.3 End users 77
5.7.1.4 Regulatory bodies 77
5.8 TECHNOLOGY ANALYSIS 78
5.8.1 KEY TECHNOLOGIES 78
5.8.1.1 High-throughput sequencing 78
5.8.1.2 Nanopore sequencing 78
5.8.1.3 Single-molecule real-time (SMRT) sequencing 78
5.8.2 COMPLEMENTARY TECHNOLOGIES 79
5.8.2.1 Bioinformatics and data analysis platforms 79
5.8.2.2 Multiplex PCR 79
5.8.2.3 5’RACE 79
5.8.3 ADJACENT TECHNOLOGIES 80
5.8.3.1 Multi-omics integration 80
5.8.3.2 Spatial genomics and transcriptomics 80
5.8.3.3 Single-cell sequencing technologies 80
5.9 PATENT ANALYSIS 81
5.10 TRADE DATA ANALYSIS 82
5.10.1 IMPORT DATA FOR HS CODE 3822, 2020−2024 82
5.10.2 EXPORT DATA FOR HS CODE 3822, 2020−2024 84
5.11 KEY CONFERENCES & EVENTS, 2025–2026 85
5.12 REGULATORY ANALYSIS 86
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.12.2 REGULATORY FRAMEWORK 88
5.12.2.1 North America 88
5.12.2.1.1 US 88
5.12.2.1.2 Canada 88
5.12.2.2 Europe 89
5.12.2.2.1 UK 89
5.12.2.3 Asia Pacific 89
5.12.2.3.1 China 89
5.12.2.3.2 Japan 90
5.12.2.3.3 South Korea 90
5.12.2.3.4 Australia 91
5.12.2.3.5 India 91
5.12.2.3.6 Rest of Asia Pacific 91
5.13 PORTER’S FIVE FORCES ANALYSIS 92
5.13.1 THREAT OF NEW ENTRANTS 93
5.13.2 THREAT OF SUBSTITUTES 93
5.13.3 BARGAINING POWER OF BUYERS 93
5.13.4 BARGAINING POWER OF SUPPLIERS 93
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 94
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 94
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 94
5.14.2 KEY BUYING CRITERIA 95
5.15 INVESTMENT & FUNDING SCENARIO 96
5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET 97
6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT 99
6.1 INTRODUCTION 100
6.2 ASSAY KITS & REAGENTS 100
6.2.1 TCR KITS 103
6.2.1.1 Human TCR kits 106
6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth 106
6.2.1.2 Mouse TCR kits 108
6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment 108
6.2.2 BCR KITS 110
6.2.2.1 Human BCR kits 113
6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake 113
6.2.2.2 Mouse BCR kits 115
6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth 115
6.2.3 OTHER ASSAY KITS & REAGENTS 118
6.3 INSTRUMENTS & SOFTWARE 120
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH 120
7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY 124
7.1 INTRODUCTION 125
7.2 SEQUENCING TECHNOLOGIES 125
7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES 128
7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth 128
7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES 130
7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth 130
7.3 LIBRARY PREPARATION TECHNOLOGIES 133
7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH 133
7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES 135
7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES 135
8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW 138
8.1 INTRODUCTION 139
8.2 SEQUENCING SERVICES 139
8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET 139
8.3 DATA ANALYSIS SERVICES 142
8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET 142
8.4 PRE-SEQUENCING SERVICES 144
8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH 144
9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION 147
9.1 INTRODUCTION 148
9.2 RESEARCH APPLICATIONS 148
9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET 148
9.3 DRUG DISCOVERY & DEVELOPMENT 151
9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH 151
9.4 CLINICAL DIAGNOSTICS 153
9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH 153
10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER 157
10.1 INTRODUCTION 158
10.2 ACADEMIC & RESEARCH INSTITUTES 158
10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET 158
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 161
10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH 161
10.4 OTHER END USERS 164
11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER 167
11.1 INTRODUCTION 168
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 168
11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH 168
11.3 ACADEMIC & RESEARCH INSTITUTES 171
11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH 171
11.4 OTHER END USERS 174
12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION 177
12.1 INTRODUCTION 178
12.2 NORTH AMERICA 178
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183
12.2.2 US 183
12.2.2.1 US to dominate North American market during forecast period 183
12.2.3 CANADA 187
12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth 187
12.3 EUROPE 191
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 191
12.3.2 GERMANY 196
12.3.2.1 Technological advancements in RNA sequencing to fuel market growth 196
12.3.3 UK 199
12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth 199
12.3.4 FRANCE 203
12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth 203
12.3.5 ITALY 207
12.3.5.1 High investments in genomic research to drive market 207
12.3.6 SPAIN 210
12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth 210
12.3.7 REST OF EUROPE 214
12.4 ASIA PACIFIC 217
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 222
12.4.2 CHINA 223
12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market 223
12.4.3 JAPAN 227
12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth 227
12.4.4 INDIA 231
12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth 231
12.4.5 SOUTH KOREA 234
12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth 234
12.4.6 AUSTRALIA 238
12.4.6.1 Increased research funding and favorable government initiatives to drive market 238
12.4.7 REST OF ASIA PACIFIC 241
12.5 LATIN AMERICA 245
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 249
12.5.2 BRAZIL 249
12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth 249
12.5.3 MEXICO 253
12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth 253
12.5.4 REST OF LATIN AMERICA 256
12.6 MIDDLE EAST 260
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 263
12.6.2 GCC COUNTRIES 264
12.6.2.1 Favorable government initiatives to drive drug development and clinical research 264
12.6.3 REST OF MIDDLE EAST 268
12.7 AFRICA 271
12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH 271
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 275
13 COMPETITIVE LANDSCAPE 276
13.1 INTRODUCTION 276
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022−2025 276
13.3 REVENUE ANALYSIS, 2022−2024 278
13.4 MARKET SHARE ANALYSIS, 2024 280
13.5 COMPANY VALUATION & FINANCIAL METRICS 283
13.5.1 COMPANY VALUATION 283
13.5.2 FINANCIAL METRICS 283
13.6 BRAND/PRODUCT COMPARISON 284
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 285
13.7.1 STARS 285
13.7.2 EMERGING LEADERS 285
13.7.3 PERVASIVE PLAYERS 285
13.7.4 PARTICIPANTS 285
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 287
13.7.5.1 Company footprint 287
13.7.5.2 Region footprint 287
13.7.5.3 Product and service footprint 288
13.7.5.4 Application footprint 289
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 290
13.8.1 PROGRESSIVE COMPANIES 290
13.8.2 RESPONSIVE COMPANIES 290
13.8.3 DYNAMIC COMPANIES 290
13.8.4 STARTING BLOCKS 290
13.8.5 COMPETITIVE BENCHMARKING 292
13.8.5.1 Detailed list of key startups/SMEs 292
13.8.5.2 Competitive benchmarking of key startups/SMEs 293
13.9 COMPETITIVE SCENARIO 294
13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES 294
13.9.2 DEALS 295
13.9.3 EXPANSIONS 296
14 COMPANY PROFILES 297
14.1 KEY PLAYERS 297
14.1.1 ILLUMINA, INC. 297
14.1.1.1 Business overview 297
14.1.1.2 Products/Services/Solutions offered 298
14.1.1.3 Recent developments 301
14.1.1.3.1 Product launches/approvals/upgrades 301
14.1.1.3.2 Deals 302
14.1.1.3.3 Expansions 302
14.1.1.4 MnM view 303
14.1.1.4.1 Key strengths 303
14.1.1.4.2 Strategic choices 303
14.1.1.4.3 Weaknesses & competitive threats 303
14.1.2 THERMO FISHER SCIENTIFIC INC. 304
14.1.2.1 Business overview 304
14.1.2.2 Products/Services/Solutions offered 305
14.1.2.3 Recent developments 307
14.1.2.3.1 Product launches/approvals/upgrades 307
14.1.2.3.2 Deals 308
14.1.2.3.3 Expansions 308
14.1.2.4 MnM view 308
14.1.2.4.1 Key strengths 308
14.1.2.4.2 Strategic choices 308
14.1.2.4.3 Weaknesses & competitive threats 308
14.1.3 PACBIO 309
14.1.3.1 Business overview 309
14.1.3.2 Products/Services/Solutions offered 310
14.1.3.3 Recent developments 312
14.1.3.3.1 Product launches/approvals/upgrades 312
14.1.3.3.2 Deals 313
14.1.3.3.3 Expansions 314
14.1.3.4 MnM view 314
14.1.3.4.1 Key strengths 314
14.1.3.4.2 Strategic choices 314
14.1.3.4.3 Weaknesses & competitive threats 314
14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC 315
14.1.4.1 Business overview 315
14.1.4.2 Products/Services/Solutions offered 316
14.1.4.3 Recent developments 318
14.1.4.3.1 Product launches/approvals/upgrades 318
14.1.4.3.2 Deals 318
14.1.4.4 MnM view 319
14.1.4.4.1 Key strengths 319
14.1.4.4.2 Strategic choices 319
14.1.4.4.3 Weaknesses & competitive threats 319
14.1.5 10X GENOMICS 320
14.1.5.1 Business overview 320
14.1.5.2 Products/Services/Solutions offered 321
14.1.5.3 Recent developments 322
14.1.5.3.1 Product launches/approvals/upgrades 322
14.1.5.4 MnM view 323
14.1.5.4.1 Key strengths 323
14.1.5.4.2 Strategic choices 323
14.1.5.4.3 Weaknesses & competitive threats 323
14.1.6 QIAGEN 324
14.1.6.1 Business overview 324
14.1.6.2 Products/Services/Solutions offered 325
14.1.6.3 Recent developments 327
14.1.6.3.1 Product launches/approvals/upgrades 327
14.1.6.3.2 Deals 328
14.1.6.3.3 Expansions 328
14.1.7 AGILENT TECHNOLOGIES 329
14.1.7.1 Business overview 329
14.1.7.2 Products/Services/Solutions offered 330
14.1.7.3 Recent developments 331
14.1.7.3.1 Deals 331
14.1.7.3.2 Expansions 331
14.1.8 DANAHER CORPORATION 332
14.1.8.1 Business overview 332
14.1.8.2 Products/Services/Solutions offered 333
14.1.8.3 Recent developments 334
14.1.8.3.1 Deals 334
14.1.9 TAKARA BIO INC. 336
14.1.9.1 Business overview 336
14.1.9.2 Products/Services/Solutions offered 337
14.1.9.3 Recent developments 339
14.1.9.3.1 Deals 339
14.1.10 ADAPTIVE BIOTECHNOLOGIES 340
14.1.10.1 Business overview 340
14.1.10.2 Products/Services/Solutions offered 341
14.1.11 BGI GROUP 342
14.1.11.1 Business overview 342
14.1.11.2 Products/Services/Solutions offered 342
14.1.11.3 Recent developments 344
14.1.11.3.1 Product launches/approvals/upgrades 344
14.1.11.3.2 Deals 345
14.1.11.3.3 Other developments 346
14.1.12 TECAN TRADING AG 347
14.1.12.1 Business overview 347
14.1.12.2 Products/Services/Solutions offered 348
14.1.12.3 Recent developments 349
14.1.12.3.1 Deals 349
14.1.13 AZENTA US INC. 350
14.1.13.1 Business overview 350
14.1.13.2 Products/Services/Solutions offered 351
14.1.14 PERSONALIS, INC. 352
14.1.14.1 Business overview 352
14.1.14.2 Products/Services/Solutions offered 353
14.1.14.3 Recent developments 354
14.1.14.3.1 Deals 354
14.1.14.3.2 Other developments 354
14.1.15 CREATIVE BIOLABS 355
14.1.15.1 Business overview 355
14.1.15.2 Products/Services/Solutions offered 355
14.2 OTHER PLAYERS 356
14.2.1 CELEMICS, INC. 356
14.2.2 CELLCARTA 356
14.2.3 IREPERTOIRE, INC. 357
14.2.4 NEW ENGLAND BIOLABS 358
14.2.5 CERBA RESEARCH 359
14.2.6 CEGAT GMBH 359
14.2.7 ELEMENT BIOSCIENCES 360
14.2.8 SEQALIS 360
14.2.9 SYNBIO TECHNOLOGIES 361
14.2.10 MEDGENOME 361
14.2.11 ENPICOM 362
15 APPENDIX 363
15.1 DISCUSSION GUIDE 363
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367
15.3 CUSTOMIZATION OPTIONS 369
15.4 RELATED REPORTS 369
15.5 AUTHOR DETAILS 370
LIST OF TABLES
TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS 40
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 50
TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS 53
TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS 63
TABLE 5 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 69
TABLE 6 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD) 71
TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS 76
TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS 76
TABLE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS 77
TABLE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: REGULATORY BODIES 77
TABLE 11 INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025 82
TABLE 12 IMPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD) 83
TABLE 13 EXPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD) 84
TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 85
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 19 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES 93
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 94
TABLE 21 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET) 95
TABLE 22 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET) 96
TABLE 23 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 100
TABLE 24 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 101
TABLE 25 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 101
TABLE 26 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 27 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 28 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 29 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 30 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 31 TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 103
TABLE 32 TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 104
TABLE 33 NORTH AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 34 EUROPE: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 35 ASIA PACIFIC: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 36 LATIN AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 37 MIDDLE EAST: TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 38 HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 39 NORTH AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 106
TABLE 40 EUROPE: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 41 ASIA PACIFIC: HUMAN TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 42 LATIN AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 107
TABLE 43 MIDDLE EAST: HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 44 MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 45 NORTH AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 46 EUROPE: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 47 ASIA PACIFIC: MOUSE TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 48 LATIN AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 49 MIDDLE EAST: MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 50 BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 111
TABLE 51 BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 111
TABLE 52 NORTH AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 53 EUROPE: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 54 ASIA PACIFIC: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 55 LATIN AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 56 MIDDLE EAST: BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 57 HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 113
TABLE 58 NORTH AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 59 EUROPE: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 60 ASIA PACIFIC: HUMAN BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 61 LATIN AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 115
TABLE 62 MIDDLE EAST: HUMAN BCR KITS MARKET, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 63 MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 64 NORTH AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 65 EUROPE: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 66 ASIA PACIFIC: MOUSE BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 67 LATIN AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 117
TABLE 68 MIDDLE EAST: MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 69 OTHER ASSAY KITS & REAGENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 70 NORTH AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 118
TABLE 71 EUROPE: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 119
TABLE 72 ASIA PACIFIC: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 119
TABLE 73 LATIN AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 120
TABLE 74 MIDDLE EAST: OTHER ASSAY KITS & REAGENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 75 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 76 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 77 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 78 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 79 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 80 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 81 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 125
TABLE 82 SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 83 SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 126
TABLE 84 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 85 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 86 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 87 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 88 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 127
TABLE 89 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET,
BY REGION, 2023–2030 (USD MILLION) 128
TABLE 90 NORTH AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 91 EUROPE: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 92 ASIA PACIFIC: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 93 LATIN AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 94 MIDDLE EAST: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 95 SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 131
TABLE 96 NORTH AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 97 EUROPE: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 98 ASIA PACIFIC: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 99 LATIN AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 100 MIDDLE EAST: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 101 LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 133
TABLE 102 NORTH AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 103 EUROPE: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 104 ASIA PACIFIC: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 105 LATIN AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 106 MIDDLE EAST: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 107 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 136
TABLE 108 NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 109 EUROPE: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 110 ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 111 LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 112 MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET,
BY REGION, 2023–2030 (USD MILLION) 137
TABLE 113 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW,
2023–2030 (USD MILLION) 139
TABLE 114 SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 115 NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 116 EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 117 ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 118 LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 141
TABLE 119 MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 141
TABLE 120 DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 121 NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 122 EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 123 ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 124 LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 125 MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 144
TABLE 126 PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144
TABLE 127 NORTH AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 128 EUROPE: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 129 ASIA PACIFIC: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 130 LATIN AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 131 MIDDLE EAST: PRE-SEQUENCING SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 146
TABLE 132 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 148
TABLE 133 IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 149
TABLE 134 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 135 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 136 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 137 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 138 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 139 IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 140 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 141 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 142 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 143 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 144 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 153
TABLE 145 IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS,
BY REGION, 2023–2030 (USD MILLION) 154
TABLE 146 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 147 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 148 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 149 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 150 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 156
TABLE 151 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 158
TABLE 152 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 153 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 154 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 155 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 156 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 157 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 161
TABLE 158 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 159 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 160 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 161 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 162 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 163 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2023–2030 (USD MILLION) 164
TABLE 164 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 165 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 166 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 167 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 168 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 169 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 170 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 168
TABLE 171 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 172 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 169
TABLE 173 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 170
TABLE 174 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 170
TABLE 175 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 171
TABLE 176 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2023–2030 (USD MILLION) 171
TABLE 177 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 178 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 179 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 180 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 181 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 182 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 173
TABLE 183 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 174
TABLE 184 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 185 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 186 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 187 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 188 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 189 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION,
2023–2030 (USD MILLION) 178
TABLE 190 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 191 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 180
TABLE 192 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 193 NORTH AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 194 NORTH AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 195 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 181
TABLE 196 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 181
TABLE 197 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 181
TABLE 198 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182
TABLE 199 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 182
TABLE 200 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 182
TABLE 201 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 183
TABLE 202 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 184
TABLE 203 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 204 US: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 205 US: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 206 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 185
TABLE 207 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 185
TABLE 208 US: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 209 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 186
TABLE 210 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 186
TABLE 211 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 187
TABLE 212 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 187
TABLE 213 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 214 CANADA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 215 CANADA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 216 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 189
TABLE 217 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 189
TABLE 218 CANADA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 189
TABLE 219 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 190
TABLE 220 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 190
TABLE 221 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 190
TABLE 222 EUROPE: KEY MACROECONOMIC INDICATORS 192
TABLE 223 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 192
TABLE 224 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 193
TABLE 225 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 226 EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 227 EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 228 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 194
TABLE 229 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 194
TABLE 230 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 194
TABLE 231 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 195
TABLE 232 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 233 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 234 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 196
TABLE 235 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 236 GERMANY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 237 GERMANY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 238 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 197
TABLE 239 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 198
TABLE 240 GERMANY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 198
TABLE 241 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 242 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 199
TABLE 243 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 199
TABLE 244 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 200
TABLE 245 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 246 UK: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 247 UK: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 248 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 201
TABLE 249 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 201
TABLE 250 UK: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 251 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 202
TABLE 252 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 202
TABLE 253 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 203
TABLE 254 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 204
TABLE 255 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 256 FRANCE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 257 FRANCE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 258 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 205
TABLE 259 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 205
TABLE 260 FRANCE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 205
TABLE 261 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 206
TABLE 262 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 206
TABLE 263 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 206
TABLE 264 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 207
TABLE 265 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 266 ITALY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 267 ITALY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 268 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 208
TABLE 269 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 209
TABLE 270 ITALY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 209
TABLE 271 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 272 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 210
TABLE 273 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 210
TABLE 274 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 211
TABLE 275 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 276 SPAIN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 277 SPAIN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 278 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 212
TABLE 279 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 212
TABLE 280 SPAIN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 212
TABLE 281 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 213
TABLE 282 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 283 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 284 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 214
TABLE 285 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 286 REST OF EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 287 REST OF EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 288 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 215
TABLE 289 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 216
TABLE 290 REST OF EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 216
TABLE 291 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216
TABLE 292 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER,2023–2030 (USD MILLION) 217
TABLE 293 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 217
TABLE 294 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 219
TABLE 295 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 219
TABLE 296 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 297 ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 298 ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 299 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 220
TABLE 300 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 221
TABLE 301 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 302 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221
TABLE 303 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 222
TABLE 304 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 222
TABLE 305 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 223
TABLE 306 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 224
TABLE 307 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 308 CHINA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 309 CHINA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 224
TABLE 310 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 225
TABLE 311 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 225
TABLE 312 CHINA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 225
TABLE 313 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 226
TABLE 314 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 226
TABLE 315 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 226
TABLE 316 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 227
TABLE 317 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 318 JAPAN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 319 JAPAN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 320 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 229
TABLE 321 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 229
TABLE 322 JAPAN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 229
TABLE 323 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 230
TABLE 324 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 230
TABLE 325 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 230
TABLE 326 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 231
TABLE 327 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 231
TABLE 328 INDIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 329 INDIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 330 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 232
TABLE 331 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 233
TABLE 332 INDIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 333 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 233
TABLE 334 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 234
TABLE 335 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 234
TABLE 336 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 235
TABLE 337 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 338 SOUTH KOREA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 339 SOUTH KOREA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 340 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 236
TABLE 341 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 236
TABLE 342 SOUTH KOREA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 343 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237
TABLE 344 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 237
TABLE 345 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 237
TABLE 346 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 238
TABLE 347 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 348 AUSTRALIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 349 AUSTRALIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 350 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 239
TABLE 351 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 240
TABLE 352 AUSTRALIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 240
TABLE 353 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240
TABLE 354 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 241
TABLE 355 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 241
TABLE 356 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 242
TABLE 357 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 358 REST OF ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 359 REST OF ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 360 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 243
TABLE 361 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 243
TABLE 362 REST OF ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 243
TABLE 363 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 244
TABLE 364 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 244
TABLE 365 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 244
TABLE 366 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245
TABLE 367 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245
TABLE 368 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 369 LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 370 LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 371 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 247
TABLE 372 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 247
TABLE 373 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 247
TABLE 374 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 248
TABLE 375 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 248
TABLE 376 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 248
TABLE 377 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 249
TABLE 378 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 250
TABLE 379 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 380 BRAZIL: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 381 BRAZIL: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 382 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 251
TABLE 383 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 251
TABLE 384 BRAZIL: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 385 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 252
TABLE 386 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 252
TABLE 387 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 252
TABLE 388 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 253
TABLE 389 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 390 MEXICO: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 391 MEXICO: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 392 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 254
TABLE 393 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 255
TABLE 394 MEXICO: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 255
TABLE 395 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 255
TABLE 396 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 256
TABLE 397 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 256
TABLE 398 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 257
TABLE 399 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 400 REST OF LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 401 REST OF LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 402 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 258
TABLE 403 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 258
TABLE 404 REST OF LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 258
TABLE 405 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 259
TABLE 406 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 259
TABLE 407 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 259
TABLE 408 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION,
2023–2030 (USD MILLION) 260
TABLE 409 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 260
TABLE 410 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 411 MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 412 MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 413 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 261
TABLE 414 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 262
TABLE 415 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 416 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262
TABLE 417 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 263
TABLE 418 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 263
TABLE 419 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 264
TABLE 420 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 264
TABLE 421 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 422 GCC COUNTRIES: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 423 GCC COUNTRIES: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 424 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY WORKFLOW, 2023–2030 (USD MILLION) 266
TABLE 425 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 266
TABLE 426 GCC COUNTRIES: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 266
TABLE 427 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267
TABLE 428 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 267
TABLE 429 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 267
TABLE 430 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 268
TABLE 431 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 432 REST OF MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269
TABLE 433 REST OF MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269
TABLE 434 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 269
TABLE 435 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270
TABLE 436 REST OF MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 437 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 270
TABLE 438 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 271
TABLE 439 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 271
TABLE 440 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 272
TABLE 441 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 442 AFRICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 443 AFRICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 444 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 273
TABLE 445 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 273
TABLE 446 AFRICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 447 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 274
TABLE 448 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 274
TABLE 449 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 275
TABLE 450 AFRICA: KEY MACROECONOMIC INDICATORS 275
TABLE 451 IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022−2025 276
TABLE 452 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET:
DEGREE OF COMPETITION, 2024 281
TABLE 453 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET:
DEGREE OF COMPETITION, 2024 282
TABLE 454 IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT 287
TABLE 455 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT 288
TABLE 456 IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT 289
TABLE 457 IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 292
TABLE 458 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 293
TABLE 459 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 294
TABLE 460 IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS,
JANUARY 2022–MARCH 2025 295
TABLE 461 IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS,
JANUARY 2022–MARCH 2025 296
TABLE 462 ILLUMINA, INC.: COMPANY OVERVIEW 297
TABLE 463 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 298
TABLE 464 ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES,
JANUARY 2022–MARCH 2025 301
TABLE 465 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025 302
TABLE 466 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 302
TABLE 467 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 304
TABLE 468 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 305
TABLE 469 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 307
TABLE 470 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025 308
TABLE 471 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 308
TABLE 472 PACBIO: COMPANY OVERVIEW 309
TABLE 473 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 310
TABLE 474 PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES,
JANUARY 2022–MARCH 2025 312
TABLE 475 PACBIO: DEALS, JANUARY 2022–MARCH 2025 313
TABLE 476 PACBIO: EXPANSIONS, JANUARY 2022–MARCH 2025 314
TABLE 477 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 315
TABLE 478 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/
SOLUTIONS OFFERED 316
TABLE 479 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 318
TABLE 480 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022–MARCH 2025 318
TABLE 481 10X GENOMICS: COMPANY OVERVIEW 320
TABLE 482 10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 321
TABLE 483 10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES,
JANUARY 2022–MARCH 2025 322
TABLE 484 QIAGEN: COMPANY OVERVIEW 324
TABLE 485 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 325
TABLE 486 QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES,
JANUARY 2022–MARCH 2025 327
TABLE 487 QIAGEN: DEALS, JANUARY 2022–MARCH 2025 328
TABLE 488 QIAGEN: EXPANSIONS, JANUARY 2022–MARCH 2025 328
TABLE 489 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 329
TABLE 490 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 330
TABLE 491 AGILENT TECHNOLOGIES: DEALS, JANUARY 2022–MARCH 2025 331
TABLE 492 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022–MARCH 2025 331
TABLE 493 DANAHER CORPORATION: COMPANY OVERVIEW 332
TABLE 494 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 333
TABLE 495 DANAHER CORPORATION: DEALS, JANUARY 2022–MARCH 2025 334
TABLE 496 TAKARA BIO INC.: COMPANY OVERVIEW 336
TABLE 497 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 337
TABLE 498 TAKARA BIO INC.: DEALS, JANUARY 2022–MARCH 2025 339
TABLE 499 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW 340
TABLE 500 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 341
TABLE 501 BGI GROUP: COMPANY OVERVIEW 342
TABLE 502 BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 342
TABLE 503 BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES,
JANUARY 2022–MARCH 2025 344
TABLE 504 BGI GROUP: DEALS, JANUARY 2022–MARCH 2025 345
TABLE 505 BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 346
TABLE 506 TECAN TRADING AG: COMPANY OVERVIEW 347
TABLE 507 TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 348
TABLE 508 TECAN TRADING AG: DEALS, JANUARY 2022–MARCH 2025 349
TABLE 509 AZENTA US INC.: COMPANY OVERVIEW 350
TABLE 510 AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 351
TABLE 511 PERSONALIS, INC.: COMPANY OVERVIEW 352
TABLE 512 PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 353
TABLE 513 PERSONALIS, INC.: DEALS, JANUARY 2022–MARCH 2025 354
TABLE 514 PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 354
TABLE 515 CREATIVE BIOLABS: COMPANY OVERVIEW 355
TABLE 516 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 355
TABLE 517 CELEMICS, INC.: COMPANY OVERVIEW 356
TABLE 518 CELLCARTA: COMPANY OVERVIEW 356
TABLE 519 IREPERTOIRE, INC.: COMPANY OVERVIEW 357
TABLE 520 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 358
TABLE 521 CERBA RESEARCH: COMPANY OVERVIEW 359
TABLE 522 CEGAT GMBH: COMPANY OVERVIEW 359
TABLE 523 ELEMENT BIOSCIENCES: COMPANY OVERVIEW 360
TABLE 524 SEQALIS: COMPANY OVERVIEW 360
TABLE 525 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW 361
TABLE 526 MEDGENOME: COMPANY OVERVIEW 361
TABLE 527 ENPICOM: COMPANY OVERVIEW 362
LIST OF FIGURES
FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD 39
FIGURE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: YEARS CONSIDERED 41
FIGURE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN 42
FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: BREAKDOWN OF PRIMARIES 44
FIGURE 5 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE ESTIMATION:
SUPPLY-SIDE ANALYSIS (2024) 45
FIGURE 6 GLOBAL PRODUCTS MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 46
FIGURE 7 GLOBAL SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 46
FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE VALIDATION FROM PRIMARY SOURCES 48
FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TOP-DOWN APPROACH 48
FIGURE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: CAGR PROJECTIONS 50
FIGURE 11 DATA TRIANGULATION METHODOLOGY 51
FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,
2025 VS. 2030 (USD MILLION) 54
FIGURE 13 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 55
FIGURE 14 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW,
2025 VS. 2030 (USD MILLION) 55
FIGURE 15 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 56
FIGURE 16 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 56
FIGURE 17 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 57
FIGURE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT 57
FIGURE 19 INCREASING ADOPTION OF PERSONALIZED MEDICINES AND RISING FOCUS ON GENOMIC RESEARCH TO DRIVE MARKET 59
FIGURE 20 US AND ASSAY KITS & REAGENTS DOMINATED NORTH AMERICAN MARKET
IN 2024 60
FIGURE 21 SEQUENCING TECHNOLOGIES TO ACCOUNT FOR LARGEST MARKET SHARE
IN 2030 60
FIGURE 22 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND LARGEST END USER MARKET SHARE IN 2025 61
FIGURE 23 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 61
FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68
FIGURE 26 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS,
BY KEY PLAYER (2024) 70
FIGURE 27 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD) 71
FIGURE 28 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET:
SUPPLY CHAIN ANALYSIS 73
FIGURE 29 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 30 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS 75
FIGURE 31 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING
(JANUARY 2015–DECEMBER 2024) 81
FIGURE 32 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS 92
FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 94
FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET) 95
FIGURE 35 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET) 95
FIGURE 36 FUNDING AND NUMBER OF PROJECTS AND SUB-PROJECTS
BY NATIONAL INSTITUTES OF HEALTH, 2021–2025 97
FIGURE 37 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET 98
FIGURE 38 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT 179
FIGURE 39 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT 218
FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022−2024) 278
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022−2024) 279
FIGURE 42 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024 280
FIGURE 43 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024 281
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 283
FIGURE 45 EV/EBITDA OF KEY PLAYERS 283
FIGURE 46 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 284
FIGURE 47 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 286
FIGURE 48 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT 287
FIGURE 49 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 291
FIGURE 50 ILLUMINA, INC.: COMPANY SNAPSHOT 298
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 305
FIGURE 52 PACBIO: COMPANY SNAPSHOT 310
FIGURE 53 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT 316
FIGURE 54 10X GENOMICS: COMPANY SNAPSHOT 321
FIGURE 55 QIAGEN: COMPANY SNAPSHOT 325
FIGURE 56 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT 330
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 333
FIGURE 58 TAKARA BIO INC.: COMPANY SNAPSHOT 337
FIGURE 59 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT 340
FIGURE 60 TECAN TRADING AG: COMPANY SNAPSHOT 348
FIGURE 61 AZENTA US INC.: COMPANY SNAPSHOT 351
FIGURE 62 PERSONALIS, INC.: COMPANY SNAPSHOT 353
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 耐火潤滑剤市場 – 2030年までの世界予測 2025-05-05
- ダイナミック・ポジショニング・システム市場 – 2030年までの世界予測 2025-05-05
- コアリング市場 – 2029年までの世界予測 2025-05-05
- マイクロカー市場 – 2032年までの世界予測 2025-05-05
- ライフサイエンス分析市場 – 2030年までの世界予測 2025-05-02